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Abstract
Background: Whole brain radiation therapy (WBRT), surgical resection, stereotactic radiosurgery (SRS), and
combinations of the three modalities are used in the management of patients with metastatic brain tumors. We
present the previously unreported survival outcomes of 275 patients treated for newly diagnosed brain metastases
at Cancer Care Northwest and Gamma Knife of Spokane between 1998 and 2008.
Methods: The effects treatment regimen, age, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS),
primary tumor histology, number of brain metastases, and total volume of brain metastases have on patient overall
survival were analyzed. Statistical analysis was performed using Kaplan-Meier survival curves, Andersen 95%
confidence intervals, approximate confidence intervals for log hazard-ratios, and multivariate Cox proportional
hazard models.
Results: The median clinical follow up time was 7.2 months. On multivariate analysis, survival statistically favored
patients treated with SRS alone when compared to patients treated with WBRT alone (p < 0.001), patients treated
with resection with SRS when compared to patients treated with SRS alone (p = 0.020), patients in ECOG-PS class 0
when compared to patients in ECOG-PS classes 2 (p = 0.04), 3 (p < 0.001), and 4 (p < 0.001), patients in the non-
small-cell lung cancer group when compared to patients in the combined melanoma and renal-cell carcinoma
group (p < 0.001), and patients with breast cancer when compared to patients with non-small-cell lung cancer
(p < 0.001).
Conclusions: In our analysis, patients benefited from a combined modality treatment approach and physicians
must consider patient age, performance status, and primary tumor histology when recommending specific
treatments regimens.
Keywords: Brain metastases, Survival, Treatment regimen, Age, Performance status, Primary tumor histology, Tumor
number, Tumor volume
Background
Brain metastases are defined as cancerous lesions in the
brain that originate and spread from an extracranial pri-
mary cancer. Brain metastases occur in 20 to 40% of
patients with systemic cancer and the incidence is grow-
ing due to advances in imaging technologies and the
treatment of extracranial disease [1]. The site of metas-
tasis often depends on the nearest location of vascular
clusters. As a consequence, the most common primary
cancers that have the ability to metastasize to the brain
are cancers that develop from the lung or breast [2].
However, metastasis to the brain originating from mela-
noma, colorectal cancer, renal-cell carcinoma, and carci-
noma of multiple other origins may also lead to the
development of one or more metastatic brain tumors
[3]. Due to a large amount of blood flow, the cerebrum
accounts for approximately 80% of all brain metastases,
while metastases that arise within the cerebellum and
brain stem account for the remaining 20% of metastatic
tumors [4].
Patients diagnosed with brain metastases have several
potential management options and treatment regimens
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control of primary cancer, presence of extracranial dis-
ease, number of brain metastases, size of brain metas-
tases, and location of brain metastases [1,5]. In general,
patients with brain metastases have a poor outlook and
survive an average of 1 to 2 months when treated with
steroid therapy alone [6]. Whole brain radiation therapy
(WBRT) has been historically a standard of care for
patients with brain metastases. WBRT takes advantage
of differences in radiobiology between tumor cells and
nervous tissue by targeting rapidly dividing tumor cells
in all areas of the brain, while minimizing damage to
the adjacent brain tissue [3]. Due to this favorable radia-
tion cell-kill therapeutic ratio, WBRT extends the survi-
val time of patients who undergo treatment to an
average of 4 to 7 months [1]. Surgical resection followed
by WBRT has proven to be a superior treatment modal-
ity than WBRT alone or surgical resection alone for
patients with a high performance status (functionally
independent and spend no more than 50% of their day
in bed) that possess a single, surgically accessible brain
metastasis [7-9]. However, surgical resection followed by
WBRT is considered an excessive and potentially
destructive treatment modality for patients with multiple
brain metastases and has not been investigated in a ran-
domized controlled trial [10].
Stereotactic radiosurgery (SRS) is a highly technical form
of radiation therapy that delivers a focused dose of radia-
tion to a single volume, while minimizing damage to
nearby, critical structures. The patient’s skull is immobi-
lized, allowing a controlled dose of radiation to be deliv-
ered to a specified target with sub-millimeter precision.
There are currently 4 devices utilized for SRS treatment:
Gamma Knife (GK) radiosurgery, linear accelerator
(LINAC) based treatment, a cyclotron-based proton beam,
and cyberknife technology [3]. Although GK remains the
“gold standard” of brain radiosurgery, published reports by
Andrews et al. [6] and Sneed et al. [11] concluded that
patient prognosis did not differ in terms of the method in
which SRS was delivered. The evidence assessing the effi-
cacy of SRS in the treatment of patients with brain metas-
tases is continuously increasing due to the fact that it is
capable of targeting any area in the brain with accuracy
and can be utilized to irradiate multiple lesions during the
same clinical treatment setting. For specific patient subsets
that have newly diagnosed brain metastases, WBRT alone,
SRS alone, SRS with WBRT, SRS with surgical resection,
or a combination of the three treatments can be the opti-
mal management approach.
We present a retrospective survival analysis of the 275
patients treated for newly diagnosed brain metastases at
Cancer Care Northwest and Gamma Knife of Spokane
between 1998 and 2008; including a comprehensive ana-
lysis of the effects treatment regimen, age, Eastern
Cooperative Oncology Group-Performance Status
(ECOG-PS), primary tumor histology, number of brain
metastases, and total volume of brain metastases have
on patient survival.
Methods
We analyzed the patient population baseline characteris-
tics and survival of 275 patients treated for newly diag-
nosed brain metastases at Cancer Care Northwest and
Gamma Knife of Spokane (Deaconess Hospital, Spokane,
WA) between 1998 and 2008. After obtaining approval
from IRB Spokane (IRB 1554) and the University of
Washington Human Subjects Division (Human Subjects
Application 36306), the following pre-treatment factors
were recorded from the patient’s medical records: age at
first brain metastasis diagnosis, ECOG-PS at first brain
metastasis diagnosis, number of brain metastases, pri-
mary tumor histology, and total volume of brain metas-
tases at the time of SRS for patients who received SRS,
or at an imaging appointment prior to the patients first
treatment session for patients who did not receive SRS.
Patients were categorized by age at first brain metastasis
diagnosis (<65 years and ≥65 years), number of brain
metastases at first diagnosis (1 tumor, 2-4 tumors, >4
tumors), primary tumor histology (non-small-cell lung
cancer, small-cell lung cancer, breast cancer, melanoma,
renal-cell carcinoma, other/unknown primary), total
volume of brain metastases in cm
3 (2.0, 2.0-3.9, 4.0-5.9,
6.0-7.9, ≥8.0), and ECOG-PS class (0, 1, 2, 3, 4).
Treatment regimens were prescribed based on the
patient’s performance status, age, control of primary
cancer, presence of extracranial disease, number of
brain metastases, size of brain metastases, location of
brain metastases, and at the discretion of the treating
physician. Of the 275 patients, 117 were treated with
WBRT alone, 65 were treated with SRS alone, 48 were
treated with WBRT with SRS, 11 were treated with sur-
gical resection with WBRT, 15 were treated with surgi-
cal resection with SRS, and 19 were treated with
surgical resection + WBRT + SRS. SRS was performed
using the Leksell
60Co Gamma Knife (model C). The
prescribed SRS dose to the 50% isodose line was com-
pleted in a single treatment and was based on the
patient’s tumor volume, tumor location, tumor shape,
prior radiation treatment, and standard Radiation Ther-
apy Oncology Group (RTOG) guidelines. The median
SRS dose was 18 Gy (13 Gy to 22 Gy). For patients
receiving WBRT, the median total dose prescribed was
30 Gy (5 Gy to 54 Gy). Length of follow-up was deter-
mined as the time interval between the date of first
treatment and the date of the most recent clinical
encounter or imaging appointment. Period of survival,
in months, was based upon the patient’s first treatment
session.
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survival differences between the treatment groups, age
groups, ECOG-PS groups, tumor volume groups, pri-
mary tumor histology groups, and number of brain
metastases groups. Andersen 95% confidence intervals
for the median survival times of the groups were con-
structed. Log-rank tests were employed to determine
statistically significant differences between the survival
curves of each group. Approximate confidence intervals
for the log hazard-ratio were calculated using the esti-
mate of standard error. Finally, the Cox proportional
hazard was used in a multivariate analysis of the treat-
ment groups, age groups, ECOG-PS groups, and primary
tumor histology groups. All statistical analyses were per-
formed using StatsDirect Version 2.5.7 (StatsDirect Ltd.,
Altrincham, UK) and SigmaPlot Version 11.0 (SYSTAT
Software, Inc. San Jose, CA). Statistical significance was
set at a p value < 0.05.
Results
We identified 275 patients treated at Cancer Care
Northwest and Gamma Knife of Spokane for newly
diagnosed brain metastases. The median patient age was
60 years (29 years to 86 years) at the time of diagnosis.
Non-small-cell lung cancer (NSCLC) was the most com-
mon primary tumor histology. Patients possessing a sin-
gle brain metastasis were the largest tumor number
category. Of the 275 total patients, ECOG-PS class was
not recorded in 162 patients and total tumor volume
was not recorded in 151 patients. Table 1 shows the
number of patients according to treatment regimen, age,
ECOG-PS class, primary tumor histology, number of
Table 1 Patient population baseline characteristics
Characteristic WBRT SRS WBRT+ SRS Surgery+ SRS Surgery + WBRT Surgery + WBRT + SRS Total
(n = 117) (n = 65) (n = 48) (n = 15) (n = 11) (n = 19) (n = 275)
Age at diagnosis, median (range) 62 (31-86) 61 (37-84) 57.5 (36-79) 57 (29-72) 60 (42-80) 60 (31-86) 60 (29-86)
<65 61 37 38 13 7 12 168
≥65 56 28 10 2 4 7 107
ECOG-PS
01 2 5 1 0 0 9
12 9 1 9 1 3 3 1 1 6 6
21 6 6 4 0 0 3 2 9
34 3 0 0 0 0 7
40 0 1 0 0 1 2
Unknown 67 35 25 11 10 14 162
Primary Tumor Histology
NSCLC 37 30 22 6 6 11 112
SCLC 18 5 1 1 2 0 27
Breast 20 8 12 0 0 2 42
Melanoma 7 7 3 4 1 3 25
Renal-cell carcinoma 5 1 1 2 0 0 9
Other 26 9 7 2 0 1 45
Unknown 4 5 2 0 2 2 15
# Brain Metastases
1 34 38 16 10 7 12 117
2-4 26 20 16 3 0 6 71
>4 9 2 7 1 0 0 19
Unknown 48 5 9 1 4 1 68
Tumor Volume (cm
3)
<2 1 18 8 1 0 2 30
2-3.9 0 16 8 2 0 3 29
4-5.9 0 6 5 3 0 1 15
6-7.9 0 6 9 0 0 2 17
≥8 0 10 11 3 0 9 33
NA/Unknown 116 9 7 6 11 2 151
ECOG-PS = Eastern Cooperative Oncology Group-Performance Status; NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; SRS = stereotactic
radiosurgery; WBRT = whole brain radiation therapy
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The median patient clinical follow-up time was 7.2
months (0.20 months to 117 months).
An initial statistical analysis was performed using uni-
variate median survival confidence intervals and hazard
ratio confidence intervals. Within each category a refer-
ence group was selected (treatment regimen = SRS
alone, age = less than 65 years, ECOG-PS = 0, primary
tumor histology = NSCLC, number of brain metastases
= 1, tumor volume = less than 2 cm
3)a n dw a st e s t e d
against the other groups’ hazard ratios. Univariate
hazard ratio analysis of treatment groups indicated that
the survival of the SRS alone treatment group was statis-
tically superior (p < 0.001) to the survival of the WBRT
alone treatment group (95% CI, 1.37-2.53). Kaplan-
Meier survival curves illustrating overall survival based
on treatment modality can be found in Figure 1. Uni-
variate hazard ratio analysis of age groups (95% CI,
1.14-1.98) indicated that survival statistically favored
patients <65 years of age (p = 0.002). Comparison of
univariate hazard ratios in relation to ECOG-PS class
indicated that survival statistically favored patients cate-
gorized in ECOG-PS class 0 when compared to patients
categorized in ECOG-PS class 2 (95% CI, 1.57-6.4) and
ECOG-PS class 3 (95% CI, 1.12-15.06), with p values of
0.006 and 0.005, respectively. Comparison of univariate
hazard ratios in relation to primary tumor histology
indicated that survival statistically favored patients with
NSCLC when compared to patients with small-cell lung
cancer (SCLC) (95% CI, 0.94-2.61) and patients in the
other primary tumor histology group (95% CI, 1.14-
2.65), with p values of 0.04 and 0.002, respectively.
Kaplan-Meier survival curves illustrating overall survival
based on primary tumor histology can be found in
Figure 2. The analysis of the number of brain metastases
groups and tumor volume groups did not yield any sta-
tistically significant results. Kaplan-Meier survival curves
showing overall survival based on the number of brain
metastases and volume of brain metastases are shown in
Figures 3 and 4.
The overall patient median survival time was deter-
mined to be 7.9 months. The median survival time for
patients treated with WBRT alone was 4.3 months (95%
CI, 3.30-5.38), 9.4 months (95% CI, 6.41-12.45) for
patients treated with SRS alone, 10 months (95% CI,
8.17-12.15) for patients treated with resection with
WBRT, 12 months (95% CI, 8.74-15.98) for patients
treated with WBRT with SRS, 13 months (95% CI, 9.70-
16.54) for patients treated with resection + WBRT +
SRS, and 24 months (95% CI, 1.73-45.55) for patients
treated with resection with SRS. Patients <65 years of
age survived a median time of 11 months (95% CI, 8.42-
12.88), while patients ≥65 years of age survived a med-
ian time of 5.7 months (95% CI, 4.29-7.09). The median
survival time for patients in ECOG-PS class 0 was 22
months (95% CI, 4.43-39.69), 9.5 months (95% CI, 3.84-
15.16) for patients in ECOG-PS class 1, 6.0 months
Figure 1 Kaplan-Meier survival curve illustrating overall
survival based on treatment modality.
Figure 2 Kaplan-Meier survival curve illustrating overall
survival based on primary tumor histology.
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1.5 months (95% CI, 0.94-1.96) for patients in ECOG-PS
class 3. In regard to primary tumor histology, the med-
ian survival time for patients with NSCLC was deter-
mined to be 9.78 months (95% CI, 7.90-11.56), 9.2
months (95% CI, 4.04-14.30) for patients with breast
cancer, 8.6 months (95% CI, 3.67-13.55) for the com-
bined melanoma and renal-cell carcinoma group, 6.7
months (95% CI, 3.47-10.01) for patients with SCLC,
and 5.7 months (95% CI, 2.66-8.72) for patients classi-
fied in the other primary tumor histology group.
Further statistical analysis was conducted using multi-
variate Cox regression analysis with hazard ratio estimates
and confidence intervals (Table 2). The multivariate ana-
lyses utilized patients treated with SRS alone, patients <65
years of age, patients in ECOG-PS class 0, and patients
with NSCLC as the reference groups. Multivariate hazard
ratio analysis of treatment groups indicated that the survi-
val of patients in the SRS alone treatment group was sta-
tistically superior (p < 0.001) to the survival of the patients
in the WBRT alone treatment group (95% CI, 1.37-2.73)
and that the survival of the resection with SRS treatment
group was statistically superior (p = 0.020) to the survival
of the SRS alone treatment group (95% CI, 0.49-0.94).
Comparison of multivariate hazard ratios in relation to
ECOG-PS class indicated that survival statistically favored
patients categorized in ECOG-PS class 0 when compared
to patients categorized in ECOG-PS class 2 (95% CI, 1.02-
2.72), ECOG-PS class 3 (95% CI, 4.28-4.91), and ECOG-
PS class 4 (95% CI, 5.98-21.2), with p values of 0.04,
<0.001, <0.001, respectively. Multivariate hazard ratio ana-
lysis of primary tumor histology groups indicated that the
survival of patients in the breast cancer group was statisti-
cally superior (p < 0.001) to the survival of patients in the
NSCLC group (95% CI, 0.78-0.96) and that the survival of
patients in the NSCLC group was statistically superior
(p < 0.001) to the survival of patients in the combined
melanoma and renal-cell carcinoma group (95% CI, 1.06-
1.3). Multivariate hazard ratio analysis of age groups did
not yield any statistically significant results.
Discussion
Patients with metastatic brain disease have a poor prog-
nosis and curative treatment is not achievable in most
clinical situations, with 50% of patients dying from their
neurological cancer rather than their extracranial cancer
[12]. Due to this unfortunate outlook, maximizing
patient’s period of survival and comfort level is of great
importance. Although several Phase III studies have been
published assessing the efficacy of different treatment
modalities, many questions still remain unanswered and
further randomized evidence is needed not only to prove
superior treatments in comparison studies, but to identify
optimal courses of treatment in unique patient subsets
Figure 4 Kaplan-Meier survival curve illustrating overall
survival based on volume of brain metastases.
Figure 3 Kaplan-Meier survival curve illustrating overall
survival based on number of brain metastases.
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clinical effects treatment regimen, age, performance sta-
tus, primary tumor histology, number of brain metas-
tases, and total volume of brain metastases have on
patient survival.
Perhaps the most questionable matter in the manage-
ment of patients with brain metastases is whether the
addition of WBRT to SRS will provide patients with a
superior prognosis when compared to patients treated
with SRS alone [3]. Our study did not find statistically
significant survival differences between the SRS alone
treatment group and the SRS with WBRT treatment
group in both univariate and multivariate analysis. In
the randomized controlled trial published by Aoyama et
al. [13], the authors evaluated the clinical outcomes of
patients treated with SRS with or without WBRT and
also witnessed no significant (p = 0.4) differences in sur-
vival between the two treatment arms. However, the
patients treated with WBRT with SRS had a substan-
tially better 12-month brain tumor recurrence rate (p <
0.001) and underwent salvage therapy (p < 0.001) less
often than the patients treated with SRS alone, but these
increases in tumor control did not affect patient survi-
val. Several retrospective cohort studies published in the
last ten years have also reported that the addition of
WBRT to SRS does not result in superior levels of
patient survival [11,18-21].
On multivariate analysis, we found that the survival of
the SRS alone treatment arm did not statistically differ
when compared to the survival of the resection with
WBRT treatment arm. These data correlate with the
Phase III randomized trial conducted by Muacevic et al.
[17]. A total of 64 patients with a single, surgically acces-
sible brain metastasis ≤30 mm in diameter, a Karnofsky
Performance Score (KPS) ≥70, and a controlled primary
cancer were randomized into a GK radiosurgery alone
group (31 patients) and a surgery with WBRT group (33
patients). The authors reported non-significant differ-
ences in survival between the two treatment groups.
Rades et al. [22] retrospectively compared SRS alone and
surgery with WBRT in 260 patients classified in RPA
class 1 or 2 [5] that were diagnosed with 1 to 2 brain
metastases and also reported that the two groups did not
differ in survival. Our multivariate analysis also found
superior levels of survival in patients treated with resec-
tion with SRS when compared to patients treated with
SRS alone. The body of world literature lacks sufficient
studies comparing patients treated with SRS alone
against patients treated with resection with SRS. How-
ever, survival differences between patients treated with
SRS alone and patients treated with resection with SRS
was recently reported in another study by Rades et al.
[23]. The authors analyzed the clinical outcomes of 164
patients of advanced age (≥65 years). Specifically, 34
patients were treated with WBRT alone, 43 patients were
treated with SRS alone, 41 patients were treated with
resection + SRS, and 46 patients were treated with resec-
tion + WBRT+ SRS boost. In contrast to our results,
which favored the resection with SRS treatment group,
the authors reported that treatment regimen influenced
survival, with the SRS alone treatment group surviving a
greater time than the resection + SRS treatment group.
The results reported by Rades et al. [23] can be explained
when considering the risks of surgery in elderly patients.
This data permits the treatment of select patients who
are <65 years of age and are functionally independent
with resection in combination with SRS.
In subset analysis, patients treated with WBRT alone
at our institution exhibited the shortest period of survi-
val, with each of the other five treatment arms surviving
a substantially greater time than the WBRT alone treat-
ment arm. Although it is likely that the treatment arms
consisted of very different patient subsets with respect
to ECOG-PS class, tumor number, tumor volume, and
extent of systemic disease, both univariate and multi-
variate analysis found statistically significant differences
Table 2 Multivariate hazard ratios, confidence intervals,
and p values
Hazard Ratio
Estimate 95% CI p value**
Treatment Groups
SRS* reference
Surgery + SRS 0.68 0.49-0.94 0.020
WBRT + SRS 0.99 0.93-1.05 0.660
Surgery + WBRT + SRS 0.79 0.61-1.02 0.070
WBRT 1.94 1.37-2.73 <0.001
Surgery + WBRT 1.04 0.76-1.43 0.800
Age at diagnosis
<65* reference
≥65 1.21 0.91-1.62 0.190
ECOG-PS
0* reference
1 1.07 0.58-1.95 0.830
2 1.67 1.02-2.72 0.040
3 4.58 4.28-4.91 <0.001
4 11.26 5.98-21.2 <0.001
Primary Tumor Histology
NSCLC* reference
SCLC 1.11 0.97-1.26 0.130
Breast 0.87 0.78-0.96 <0.001
Melanoma and Renal-cell 1.17 1.06-1.3 <0.001
Other 1.41 0.95-2.1 0.080
ECOG-PS = Eastern Cooperative Oncology Group-Performance Status; NSCLC =
non-small-cell lung cancer; SCLC = small-cell lung cancer; SRS = stereotactic
radiosurgery; WBRT = whole brain radiation therapy
* Reference group against which other groups’ survival experience are
compared
** p value for test if groups’ survival experience is same as reference group
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and the hazard ratio of patients treated with SRS alone.
No randomized controlled trials have been conducted
assessing patients treated with SRS alone compared with
patients treated with WBRT alone. However, in a recent
literature review, Linskey et al. [12] found level 3 evi-
dence indicating that patients with 1 to 3 brain metas-
tases that are treated with SRS alone have superior
levels of survival when compared to patients treated
with WBRT alone.
As expected, we found that age and performance sta-
tus are both significant predictors in determining patient
prognosis, as survival statistically favored patients <65
years old in univariate analysis and patients in a lower
ECOG-PS class in both univariate and multivariate ana-
lysis. Several comparison studies have reported a survi-
val dependency on patient age and performance status.
Sanghavi et al. [24] retrospectively analyzed the out-
comes and potential prognostic factors of a total of 502
patients treated with SRS with WBRT and 1200 patients
treated with WBRT alone and found that survival was
more pronounced in patients with a higher KPS (p =
0.0001), a controlled primary cancer (p = 0.0023), the
absence of extracranial cancer (p = 0.0001), and a lower
RPA class (p = 0.000007). Kocher et al. [25] compared
the efficacy of SRS alone against WBRT alone in 255
patients with 1 to 3 brain metastases and reported sta-
tistically significant increases in median survival in
patients categorized in RPA class 1 (p < 0.0001) and
RPA class 2 (p < 0.04). Frazier et al. [26] retrospectively
analyzed 237 patients treated with SRS ± WBRT and
also found that survival statistically favored patients that
were <65 years of age (p = 0.008) with KPS values >70
(p = 0.034).
The number and volume of brain metastases patients
possess at the time of diagnosis are crucial factors in
prescribing the most advantageous course of treatment
in select patient groups. When evaluating our six treat-
ment arms in univariate analysis; however, the number
and size of brain metastases did not influence patient
survival. Tumor resection in combination with WBRT
and/or SRS in treating patients with a single brain
metastasis is recommended for those who present with
severe neurologic deficits, a ventricular obstruction, or a
tumor of a large intracranial volume (which often pro-
duces mass effect) [1]. When the patient has controlled
neurological symptoms, a tumor/s of a small intracranial
volume, a single brain metastasis, a surgically inoperable
brain metastasis, or multiple brain metastases, SRS
alone or in combination with WBRT is often the recom-
mended course of treatment [1]. Questions remain
regarding the survival dependency on the number and
size of brain metastases patient groups possess. Studies
have shown increased survival levels in patients with a
single brain metastasis that were treated with radiosur-
gery [6,26]. However, other publications have reported
that tumor volume has a greater impact on patient sur-
vival than number of brain metastases and primary
tumor histology, with patients possessing small tumor
volumes surviving a greater period of time [27-30].
Further study and research is needed on how the num-
ber and total volume of brain metastases affect patient
survival.
The histologic subtype of the primary tumor may be
an essential predictor in assessing the survival advantage
of specific patient subsets. NSCLC is known to produce
the greatest amount of metastatic brain lesions [31,32].
In univariate analysis, survival statistically favored
patients with NSCLC when compared to patients with
SCLC and patients classified in the other primary histol-
ogy group. In multivariate analysis; however, survival
statistically favored patients in the breast cancer group
when compared to patients in the NSCLC group.
Increases in the survival of breast cancer patients when
compared to NSCLC patients was also recently reported
in the survival analysis of 237 patients treated with
radiosurgery by Frazier et al. [26]. These results are
likely due to advances in the surgical and chemothera-
peutic care of breast cancer patients [33]. It was also
observed in multivariate analysis that survival statisti-
cally favored patients with NSCLC when compared to
the combined melanoma and renal-cell carcinoma
group. Traditionally, melanoma and renal-cell carcinoma
have been classified as “radioresistant” tumor histologies
because of their negative response to standard radiation
treatment. However, several studies have reported posi-
tive outcomes when treating patients with melanoma
and renal-cell carcinoma primaries with radiosurgery
[34-40]. In a phase II trial conducted by Manon et al.
[41], 31 patients diagnosed with melanoma, renal-cell
carcinoma, and sarcoma primary cancers with 1 to 3
brain metastases were treated with SRS alone. The 3
and 6 month intracranial failure rate for the evaluated
patients was found to be 25.8 and 48.3%, respectively.
The authors concluded that delaying WBRT for patients
with melanoma, renal-cell carcinoma, and sarcoma pri-
mary cancers may be appropriate for specific subgroups
of patients, but must be approached with caution.
Conclusions
We report retrospectively on the effects treatment regi-
men, age, performance status, primary tumor histology,
number of brain metastases, and volume of brain metas-
tases have on the survival of patients diagnosed with
brain metastases. Multivariate analysis of treatment regi-
mens showed that survival statistically favored patients
treated with SRS alone and patients treated with resec-
tion with SRS when compared to patients treated with
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respectively. Comparison of multivariate hazard ratios in
relation to ECOG-PS class indicated that survival statis-
tically favored patients categorized in ECOG-PS class 0
when compared to patients categorized in ECOG-PS
classes of 2, 3, and 4. Multivariate analysis of primary
tumor histology groups indicated that the survival of
patients in the breast cancer group was statistically
superior to the survival of patients in the NSCLC group
and that the survival of patients in the NSCLC group
was statistically superior to the survival of patients in
the combined melanoma and renal-cell carcinoma
group. In our analysis, patients benefited from a com-
bined modality treatment approach and physicians must
consider patient age, performance status, and primary
tumor histology when recommending specific treatment
regimens.
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